An interventional study of Dry Needling and Sham Dry Needling in Multiple Sclerosis, sponsored by University of South Florida. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by University of South Florida · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,192 studies in Multiple Sclerosis with a site in United States — 184 open to participants now, 258 under way, 23 of them phase 3. Multiple Sclerosis · United States.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, this one is the 620th largest by planned enrollment of the 879 interventional ones that give a count, is one of 44 that started in 2026, is one of 381 with no phase, reaches primary completion later than 113 of the 255 other live ones, and was the 1,166th registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →184 of the 1,192 studies in Multiple Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Sundance Biosciences, Inc. · Sites in United States
Ages 18–70
Genentech, Inc. · Sites in United States, Puerto Rico
Ages 18–65
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 40–70
University of Texas at Austin · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,192 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 142 · Phase 2 191 · Phase 3 142 · Phase 4 82
First in 1976; this study’s year is marked. 44 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 50 across the 879 interventional studies, 100 across the 302 observational. Of the 819 that completed or were terminated, 332 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
376 of 1,192 have an industry lead sponsor. The 10 most frequent:
University of South Florida is the lead sponsor of 340 studies on the registry; 65 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.
University of South Florida has 6 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
78 of the studies in Multiple Sclerosis with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05134441Phase 3Immunic AGStudy to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | 2026-11 |
| NCT05877963Phase 3TG Therapeutics, Inc.Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | 2027-01-21 |
| NCT06136728Phase 3MGH Institute of Health ProfessionsDalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis | 2027-05 |
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 78 to your calendar (.ics) → With an account.
Among the 1,192 studies in Multiple Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted at the Human Functional Performance Laboratory in the School of Physical Therapy and Rehabilitation Sciences (MDT Building) at the University of South Florida. The study is supported by the Consortium of Multiple Sclerosis Centers.
The investigators are conducting this study to determine whether a treatment called dry needling can improve chronic pain in the lower body (from the low back to the foot) in people with Multiple Sclerosis. Dry needling involves inserting tiny needles, similar to those used in acupuncture, into specific muscles, such as the thigh or calf muscles. Unlike traditional acupuncture, dry needling targets specific muscle areas to reduce muscle stiffness and pain. Dry needling may help reduce pain without medication. The investigators also aim to determine whether dry needling can improve balance and walking abilities, potentially leading to better day-to-day functioning.
Participants will be assigned to one of two groups. Both groups will receive six treatment sessions. One group will receive actual dry needling, while the other group will receive a sham procedure designed to mimic dry needling. Treatment assignment will be determined randomly, similar to flipping a coin. Neither participants nor the study doctor will choose the assigned treatment. Each participant will have an equal chance of receiving actual dry needling or the sham procedure. Participants will not be informed of the assigned treatment; however, the study doctor will know the treatment assignment.
Participants are being invited to take part in this study because of a diagnosis of Multiple Sclerosis and the presence of chronic pain in the lower body, including the buttocks, thighs, calves, or feet. The investigators aim to determine whether dry needling can help reduce chronic lower-body pain in people with Multiple Sclerosis.
The criteria were revised on the registry on Oct 29, 2026. See what changed
**Inclusion Criteria:**
**Exclusion Criteria:**
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Dry Needling
Procedure: Sham Dry Needling
Participants will receive dry needling treatment targeting lower-extremity muscles associated with chronic pain in people with multiple sclerosis. The intervention will be delivered over six treatment sessions by a licensed physical therapist trained in dry needling techniques.
Participants assigned to the sham dry needling group will receive a control procedure designed to mimic the experience of dry needling without therapeutic needle insertion into the target muscle tissue. The procedure will be delivered over six sessions by a licensed physical therapist trained in dry needling and sham procedures.
Percentage of Planned Dry Needling Treatment Sessions Completed
Treatment adherence will be calculated as the number of completed treatment sessions divided by the total number of planned sessions, multiplied by 100. Each participant is scheduled to receive six treatment sessions. Adherence will range from 0% to 100%, with higher percentages indicating better adherence. The feasibility target is completion of at least 80% of planned sessions.
Time frame: immediately after the intervention
Percentage of Dry Needling Sites With an Elicited Local Twitch Response
Practicality will be measured as the percentage of treated muscle sites at which a local twitch response (LTR) is elicited during actual dry needling. An LTR is a brief, involuntary muscle contraction that may occur when a needle stimulates a sensitive area within a muscle. The percentage will be calculated as the number of needling sites with an observed LTR divided by the total number of needling sites assessed, multiplied by 100. Values range from 0% to 100%, with higher percentages indicating more frequent elicitation of an LTR.
Time frame: immediately after the intervention
Treatment Credibility Score on the Credibility/Expectancy Questionnaire
Treatment credibility will be assessed using the credibility subscale of the Credibility/Expectancy Questionnaire (CEQ), which measures how logical and believable participants consider the treatment. The subscale consists of three items scored from 1 to 9, producing a total score ranging from 3 to 27. Higher scores indicate greater treatment credibility and a more favorable outcome.
Time frame: immediately after the intervention
Number of Serious Adverse Events During Study Participation
Safety will be assessed by recording the number of serious adverse events occurring during study participation. Serious adverse events include events resulting in death, life-threatening conditions, hospitalization, persistent or significant disability, or other medically important conditions. The total number of serious adverse events will be reported for each treatment group. Fewer serious adverse events indicate a more favorable safety outcome. The feasibility hypothesis is that no serious adverse events will occur.
Time frame: immediately after the intervention
The Patient-Reported Outcomes Measurement Information System Pain Intensity
Change in Pain Intensity Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Intensity Short Form 3a (Raw Score: 3-15; Higher Scores Indicate Worse Outcomes)
Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion
Change in Pressure Pain Threshold Measured Using a Pressure Algometer
Pressure pain threshold (PPT) will be assessed using a pressure algometer to measure mechanical pain sensitivity. Pressure will be gradually applied to selected muscle sites until participants first report that the pressure becomes painful. Higher PPT values indicate lower pain sensitivity and better outcomes. Changes from baseline will be compared between the actual and sham dry needling groups.
Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
Change in Walking Performance Measured by the Timed 25-Foot Walk Test
Walking performance will be assessed using the Timed 25-Foot Walk (T25FW) test. Participants will be instructed to walk a distance of 25 feet as quickly and safely as possible. The time required to complete the test will be recorded in seconds. Lower completion times indicate faster walking speed and better mobility. Changes from baseline will be compared between the actual and sham dry needling groups.
Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
Change in Functional Mobility Measured by the Timed Up and Go Test
Functional mobility will be assessed using the Timed Up and Go (TUG) test. Participants will stand up from a chair, walk 3 meters, turn around, walk back to the chair, and sit down. The total time required to complete the test will be recorded in seconds. Lower completion times indicate better functional mobility. Changes from baseline will be compared between the actual and sham dry needling groups.
Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
Change in Postural Sway Measured by an Accelerometer During Static Standing
Static standing balance will be assessed using a body-worn accelerometer to measure postural sway during quiet standing. Postural sway refers to the movement of the body while maintaining a standing position. Greater sway magnitude indicates poorer balance, while lower values indicate better postural stability. Changes from baseline will be compared between the actual and sham dry needling groups.
Time frame: Baseline, 3 weeks (post-treatment), and 1 month after treatment completion.
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for May 2027, 11 months after the start.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 11 months is below that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.